Wegovy 0.5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9CVX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,459
Award facts
- Contract value 100% obligated
- $10,458.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,458.86 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 8, 2026, for Wegovy 0.5 mg/0.5 mL pen injections, with completion targeted for January 9, 2026. The product will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order was awarded without set-aside restrictions on a fully competitive basis, demonstrating the contractor's capability to meet federal pharmaceutical procurement requirements. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc., which does business as AmerisourceBergen, a major pharmaceutical distributor serving federal healthcare systems.
This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract value: $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, and vaccines to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Wegovy, a GLP-1 receptor agonist indicated for weight management, represents one component of the diverse therapeutic portfolio delivered under this prime vendor arrangement.
Quick answers
Who was awarded contract SPE2DR26F9CVX?
SPE2DR26F9CVX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F9CVX worth?
The government has obligated $10,459 on SPE2DR26F9CVX.
Is contract SPE2DR26F9CVX an order under another contract?
Yes. SPE2DR26F9CVX is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9CVX competed?
The extent of competition for SPE2DR26F9CVX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award